44
Vol. 66, No. 2 2015
Northeast Florida Medicine
CME
7. Metzger ML and Dome JS. Current Therapy for Wilms’
Tumor.
Oncologist.
2005 Nov-Dec;10(10):815-826.
PubMed PMID: 16314292.
8. Beckwith JB and Palmer NF. Histopathology and prog-
nosis of Wilms’ tumors: results from the First National
Wilms’ Tumor Study.
Cancer.
1978 May;41(5):1937–
1948. PubMed PMID: 206343
9. Green DM, Breslow NE, Beckwith JB et al. Treatment
with nephrectomy only for small, stage I/favorable his-
tology Wilms’ tumor: a report from the National Wilms’
Tumor Study Group.
J Clin Oncol.
2001 Sep 1;19:3719–
3724. PubMed PMID: 11533093.
10. Grundy PE, Breslow N, Li S et al. Loss of Heterozygosity
for Chromosomes 1p and 16q is an Adverse Prognostic
Factor in Favorable Histology Wilms’ Tumor. A Report
from the National Wilms’ Tumor Study Group.
J Clin
Oncol.
2005 Oct 10;23(29):7312–7321. PubMed PMID:
16129848.
11. Grundy PE, Green DM, Dirks AC, et al. Clinical signifi-
cance of pulmonary nodules detected by CT and not CXR
in patients treated for favorable histology Wilms tumor on
national Wilms tumor studies-4 and -5: a report from the
Children’s Oncology Group.
Pediatr Blood Cancer.
2012
Oct;59(4):631-5. PubMed PMID: 22422736.
12. Abu-Ghosh AM, Krailo MD, Goldman SC et al. Ifosfa-
mide, carboplatin and etoposide in children with poor-risk
relapsed Wilms’ tumor: a Children’s Cancer Group report.
Ann Oncol.
2002 March;13(3):460–469. PubMed
PMID: 11996479.
13. Green DM, Breslow NE, Ii Y et al. The role of surgical
excision in the management of relapsed Wilms’ tumor
patients with pulmonary metastases: a report from the
National Wilms’ Tumor Study.
J Pediatr Surg.
1991
Jun;26(6):728–733. PubMed PMID: 1658286.
14. Marina NM, Wilimas JA, Meyer WH et al. Refining ther-
apeutic strategies for patients with resistant Wilms’ tumor.
Am J Pediatr Hematol Oncol.
1994 Nov;16(4):296–300.
PubMed PMID: 7978044.
